降低致动脉粥样硬化性脂蛋白的VLDLR基因治疗研究  

Study on VLDLR Gene Therapy for Reducing Atherogenic Lipoprotein

作　　者：关桢婷 胡小菁 尹显明 

机构地区：[1]西安医学院研究生处,陕西 西安 [2]西安市第九医院心血管内科,陕西 西安

出　　处：《临床医学进展》2023年第3期3424-3430,共7页Advances in Clinical Medicine

摘　　要：目前大多数心血管疾病(CVD)的治疗和管理策略都围绕低密度脂蛋白胆固醇(LDL-C),但越来越多的研究发现,将LDL-C水平控制在目标靶点值后,部分患者心血管不良事件仍然存在,并将残余CVD风险归因于高甘油三酯(TG)和高脂蛋白(a)。VLDLR能够结合和内吞含apoE的富含TG的脂蛋白以及Lp(a),但它在肝脏中通常不表达。靶向肝VLDLR表达有可能促进这些致动脉粥样化颗粒的清除。这篇综述概述了VLDLR的功能以及开发靶向肝VLDLR表达的基因药物的潜力。At present, most treatment and management strategies for cardiovascular disease (CVD) revolve around low density lipoprotein cholesterol (LDL-C). However, more and more studies have found that after the level of LDL-C is controlled at the target value, cardiovascular adverse events still exist in some patients, and the residual CVD risk is attributed to high triacylglycerol (TG) and high lipo-protein(a). VLDLR can bind to and swallow TG-rich lipoprotein and Lp(a) containing apoE, but it is usually not expressed in the liver. The expression of VLDLR in targeted liver may promote the clearance of these atherogenic granules. This review outlines the function of VLDLR and the poten-tial for developing gene drugs targeting liver VLDLR expression.

关 键 词：极低密度脂蛋白受体(VLDLR) 甘油三酯(TG) 基因治疗 

分 类 号：R54[医药卫生—心血管疾病]